Ann Intern Med. 2011 Oct 4;155(7):479-80. doi: 10.7326/0003-4819-155-7-201110040-00017.
Hepatitis E virus (HEV) infections in immunosuppressed patients can result in chronic hepatitis that rapidly progresses to cirrhosis (1, 2). When immunosuppressed transplant recipients are treated with pegylated -interferon and ribavirin, HEV clears and liver histology improves (2). However, we are not aware of reports about how this therapy works in patients with HIV infection.
To describe the clinical and laboratory response to antiviral therapy for chronic HEV infection in a patient also infected with HIV.
We studied a 48-year-old bisexual male with HIV- 1 infection who was chronically infected with HEV genotype 3a and had several years of painful sensory neuropathy of uncertain cause in the lower limbs (3). He had malaise, persistently abnormal liver function tests, and active inflammation and cirrhosis on liver biopsy (Figure).Before beginning anti-HEV therapy, the patient had an undetectable HIV viral load and a CD4 cell count between 30 and 150 cells/mL for the previous 2 years while receiving combination antiretroviral therapy (abacavir–lamivudine once daily and lopinavir–ritonavir twice daily).
免疫抑制患者的戊型肝炎病毒(HEV)感染可导致迅速进展为肝硬化的慢性肝炎(1,2)。当免疫抑制的移植受者接受聚乙二醇干扰素和利巴韦林治疗时,HEV 清除且肝脏组织学改善(2)。然而,我们尚未了解关于该疗法在 HIV 感染患者中的作用的报告。
描述一名同时感染 HIV 的慢性 HEV 感染患者接受抗病毒治疗的临床和实验室反应。
我们研究了一名 48 岁的双性恋男性,他感染了 HIV-1,慢性感染 HEV 基因型 3a,下肢有多年原因不明的疼痛性感觉神经病(3)。他有不适、持续的肝功能异常以及肝脏活检显示活跃的炎症和肝硬化(图)。在开始抗 HEV 治疗之前,该患者的 HIV 病毒载量无法检测,并且在过去 2 年中接受联合抗逆转录病毒治疗(每日一次阿巴卡韦-拉米夫定和每日两次洛匹那韦-利托那韦)时,CD4 细胞计数在 30 至 150 个细胞/毫升之间。